- Conditions
- Hypervascular Tumors, Bleeding, Hemorrhage
- Interventions
- Obsidio™ Conformable Embolic
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • Stockton, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
- Interventions
- Treatment with HydroPearl via radial access
- Device
- Lead sponsor
- Terumo Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 3 more
- Conditions
- Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck
- Interventions
- Iodixanol, Angiogram, Arterial Embolization, Polyvinyl Alcohol, Ethiodized Oil, Computed Tomography, Chart Abstraction
- Other · Procedure · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hypervascular Tumors
- Interventions
- Instylla HES, TAE or cTACE
- Device · Other
- Lead sponsor
- Instylla, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 9 more
- Conditions
- Hepatocellular Carcinoma, Neuroendocrine Tumors
- Interventions
- TACE Catheters
- Device
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania